Products
Besufetamig Biosimilar Bispecific Antibody (PD-1 × CD3) for Research
Cat No.: GMP-Bios-INN-1100
Anti-PDCD1/CD279/PD1 therapeutic antibody (Pre-made Besufetamig biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Besufetamig (development code ONO-4685) is a bispecific antibody targeting PD-1 (PDCD1) and CD3. It is developed by Ono Pharmaceutical for T-cell malignancies. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1100-1mg | 1mg | |
| GMP-Bios-INN-1100-10mg | 10mg | |
| GMP-Bios-INN-1100-100mg | 100mg | |
| GMP-Bios-INN-1100-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Besufetamig biosimilar, Bispecific mAb, Anti-PDCD1/CD279/PD1;CD3E Antibody: Anti-PD-1/CD279/PDCD1/Programmed cell death protein 1 therapeutic antibody |
| INN Name | Besufetamig |
| Target | PDCD1/CD279/PD1;CD3E |
| Format | Bispecific mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;G1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | TBC |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2025 |
| Year Recommended | na |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | TBC |
